201 related articles for article (PubMed ID: 36686606)
1. Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances.
Nasiri-Ansari N; Kassi E
Metabol Open; 2023 Mar; 17():100229. PubMed ID: 36686606
[No Abstract] [Full Text] [Related]
2. [Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016].
Chen YS; Wang BY; Li YM
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):181-186. PubMed ID: 28482404
[TBL] [Abstract][Full Text] [Related]
3. [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].
Liu Y; Feng PP; Zhu W; Gong JP
Zhonghua Gan Zang Bing Za Zhi; 2017 Jun; 25(6):473-476. PubMed ID: 28763870
[TBL] [Abstract][Full Text] [Related]
4. [Advances in the pathogenesis of non alcoholic fatty liver disease].
Pár A; Pár G
Orv Hetil; 2017 Jun; 158(23):882-894. PubMed ID: 28580850
[TBL] [Abstract][Full Text] [Related]
5. [Non-alcoholic fatty liver disease and steatohepatitis].
Pár G; Horváth G; Pár A
Orv Hetil; 2013 Jul; 154(29):1124-34. PubMed ID: 23853345
[TBL] [Abstract][Full Text] [Related]
6. [Non alcoholic fatty liver disease: a new risk factor for cardiovascular disease?].
Sdiri W; Romdhane H; Mbarek D; Ben Abdallah H; Longo S; Abdelli MN; Boujnah MR
Tunis Med; 2013 Mar; 91(3):171-4. PubMed ID: 23588628
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
Federico A; Trappoliere M; Loguercio C
Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
[TBL] [Abstract][Full Text] [Related]
8. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Méndez-Sánchez N; Díaz-Orozco LE
Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
Athyros VG; Katsiki N; Doumas M
Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
[No Abstract] [Full Text] [Related]
10. [Non - alcoholic fatty liver disease and enteral insufficiency: comorbidity of their development].
Vakhrushev YM; Suchkova EV; Lukashevich AP
Ter Arkh; 2019 Dec; 91(12):84-89. PubMed ID: 32598594
[TBL] [Abstract][Full Text] [Related]
11. Docosahexaenoic acid and non-alcoholic fatty liver disease in obese children: a novel approach?
Verduci E; Lassandro C; Radaelli G; Soldati L
J Transl Med; 2015 Apr; 13():109. PubMed ID: 25889212
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in understanding and managing non-alcoholic fatty liver disease.
Albhaisi S; Sanyal A
F1000Res; 2018; 7():. PubMed ID: 29946426
[TBL] [Abstract][Full Text] [Related]
14. Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases.
Shabangu CS; Huang JF; Hsiao HH; Yu ML; Chuang WL; Wang SC
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466319
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets.
Blas-García A; Cubero FJ
Front Pharmacol; 2022; 13():1072353. PubMed ID: 36438803
[No Abstract] [Full Text] [Related]
16. Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease.
Liguori A; Zoncapè M; Tsochatzis EA
Rev Esp Enferm Dig; 2022 Apr; 114(4):191-194. PubMed ID: 35187942
[TBL] [Abstract][Full Text] [Related]
17. Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide.
Méndez-Sánchez N; Zheng MH; Kawaguchi T; Sarin SK
Med Sci Monit; 2022 Aug; 28():e938080. PubMed ID: 36017581
[TBL] [Abstract][Full Text] [Related]
18. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
Yu XD; Wang JW
Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.
Hashimoto E; Tokushige K; Ludwig J
Hepatol Res; 2015 Jan; 45(1):20-8. PubMed ID: 24661406
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and therapeutic strategies for non-obese type of non-alcoholic fatty liver diseases].
Chen HT; Zhou YJ
Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):203-207. PubMed ID: 32306652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
